aTyr Pharma (ATYR) Competitors

aTyr Pharma logo
$4.08 -0.91 (-18.24%)
Closing price 04:00 PM Eastern
Extended Trading
$4.18 +0.10 (+2.45%)
As of 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ATYR vs. XBIT, XLO, RNTX, ONCY, and BOLD

Should you buy aTyr Pharma stock or one of its competitors? aTyr Pharma's main competitors and comparable companies include XBiotech (XBIT), Xilio Therapeutics (XLO), Rein Therapeutics (RNTX), Oncolytics Biotech (ONCY), and Boundless Bio (BOLD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does aTyr Pharma compare to XBiotech?

XBiotech (NASDAQ:XBIT) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

XBiotech's return on equity of -33.03% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
XBiotechN/A -33.03% -31.57%
aTyr Pharma N/A -102.83%-70.56%

aTyr Pharma has a consensus price target of $5.00, indicating a potential upside of 0.20%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than XBiotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
aTyr Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33

XBiotech has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

XBiotech has higher earnings, but lower revenue than aTyr Pharma. XBiotech is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A-$45.54M-$1.43N/A
aTyr Pharma$190K66.97-$74.12M-$21.83N/A

In the previous week, aTyr Pharma had 4 more articles in the media than XBiotech. MarketBeat recorded 5 mentions for aTyr Pharma and 1 mentions for XBiotech. aTyr Pharma's average media sentiment score of 0.22 beat XBiotech's score of -0.61 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
XBiotech Negative
aTyr Pharma Neutral

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 21.1% of XBiotech shares are owned by insiders. Comparatively, 5.0% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

aTyr Pharma beats XBiotech on 9 of the 14 factors compared between the two stocks.

How does aTyr Pharma compare to Xilio Therapeutics?

aTyr Pharma (NASDAQ:ATYR) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, aTyr Pharma had 4 more articles in the media than Xilio Therapeutics. MarketBeat recorded 5 mentions for aTyr Pharma and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.69 beat aTyr Pharma's score of 0.22 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
aTyr Pharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Xilio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

aTyr Pharma has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market.

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 5.0% of aTyr Pharma shares are owned by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

aTyr Pharma has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -20.89%. Xilio Therapeutics' return on equity of -60.54% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
aTyr PharmaN/A -102.83% -70.56%
Xilio Therapeutics -20.89%-60.54%-24.76%

Xilio Therapeutics has higher revenue and earnings than aTyr Pharma. Xilio Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
aTyr Pharma$190K66.97-$74.12M-$21.83N/A
Xilio Therapeutics$43.77M1.22-$35.04M-$0.40N/A

aTyr Pharma currently has a consensus target price of $5.00, suggesting a potential upside of 0.20%. Xilio Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 112.20%. Given Xilio Therapeutics' higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than aTyr Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
aTyr Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33
Xilio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Xilio Therapeutics beats aTyr Pharma on 8 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Rein Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 1,583.50%. aTyr Pharma has a consensus price target of $5.00, suggesting a potential upside of 0.20%. Given Rein Therapeutics' higher probable upside, equities research analysts plainly believe Rein Therapeutics is more favorable than aTyr Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
aTyr Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 1.5% of Rein Therapeutics shares are owned by company insiders. Comparatively, 5.0% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, aTyr Pharma had 1 more articles in the media than Rein Therapeutics. MarketBeat recorded 5 mentions for aTyr Pharma and 4 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.17 beat aTyr Pharma's score of 0.22 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rein Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
aTyr Pharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rein Therapeutics has higher earnings, but lower revenue than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rein TherapeuticsN/AN/A-$49.87M-$1.72N/A
aTyr Pharma$190K66.97-$74.12M-$21.83N/A

Rein Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Rein Therapeutics' return on equity of 0.00% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Rein TherapeuticsN/A N/A -69.69%
aTyr Pharma N/A -102.83%-70.56%

Summary

Rein Therapeutics beats aTyr Pharma on 9 of the 14 factors compared between the two stocks.

How does aTyr Pharma compare to Oncolytics Biotech?

aTyr Pharma (NASDAQ:ATYR) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 5.0% of aTyr Pharma shares are owned by company insiders. Comparatively, 4.7% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Oncolytics Biotech had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 6 mentions for Oncolytics Biotech and 5 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.22 beat Oncolytics Biotech's score of -0.19 indicating that aTyr Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
aTyr Pharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oncolytics Biotech
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

aTyr Pharma currently has a consensus target price of $5.00, indicating a potential upside of 0.20%. Oncolytics Biotech has a consensus target price of $5.00, indicating a potential upside of 1,207.19%. Given Oncolytics Biotech's higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than aTyr Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
aTyr Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33
Oncolytics Biotech
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

aTyr Pharma has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Oncolytics Biotech has lower revenue, but higher earnings than aTyr Pharma. Oncolytics Biotech is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
aTyr Pharma$190K66.97-$74.12M-$21.83N/A
Oncolytics BiotechN/AN/A-$28.76M-$0.32N/A

Oncolytics Biotech's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
aTyr PharmaN/A -102.83% -70.56%
Oncolytics Biotech N/A N/A -477.70%

Summary

aTyr Pharma beats Oncolytics Biotech on 7 of the 13 factors compared between the two stocks.

How does aTyr Pharma compare to Boundless Bio?

aTyr Pharma (NASDAQ:ATYR) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Boundless Bio's return on equity of -70.98% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
aTyr PharmaN/A -102.83% -70.56%
Boundless Bio N/A -70.98%-50.99%

Boundless Bio has lower revenue, but higher earnings than aTyr Pharma. Boundless Bio is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
aTyr Pharma$190K66.97-$74.12M-$21.83N/A
Boundless BioN/AN/A-$58.20M-$2.47N/A

61.7% of aTyr Pharma shares are held by institutional investors. 5.0% of aTyr Pharma shares are held by insiders. Comparatively, 23.1% of Boundless Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

aTyr Pharma currently has a consensus price target of $5.00, suggesting a potential upside of 0.20%. Given aTyr Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe aTyr Pharma is more favorable than Boundless Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
aTyr Pharma
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33
Boundless Bio
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, aTyr Pharma had 3 more articles in the media than Boundless Bio. MarketBeat recorded 5 mentions for aTyr Pharma and 2 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.29 beat aTyr Pharma's score of 0.22 indicating that Boundless Bio is being referred to more favorably in the news media.

Company Overall Sentiment
aTyr Pharma Neutral
Boundless Bio Positive

aTyr Pharma has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Boundless Bio has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market.

Summary

aTyr Pharma beats Boundless Bio on 8 of the 14 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATYR vs. The Competition

MetricaTyr PharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$10.40M$3.97B$7.59B$11.72B
Dividend YieldN/A3.63%2.47%4.48%
P/E Ratio-0.1924.6233.5830.13
Price / Sales54.7615.448.255.59
Price / CashN/A22.9521.0121.90
Price / Book0.314.164.443.72
Net Income-$74.12M-$24.10M$3.50B$393.88M
7 Day Performance-39.73%-8.44%-6.53%-6.07%
1 Month Performance-41.38%-6.54%-4.93%-7.38%
1 Year Performance-85.45%-6.71%-1.73%-7.48%

aTyr Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATYR
aTyr Pharma
3.1293 of 5 stars
$4.08
-18.2%
$5.00
+22.5%
-81.7%$10.40M$190KN/A58
XBIT
XBiotech
0.8624 of 5 stars
$1.91
+1.1%
N/A-27.9%$59.45MN/AN/A87
XLO
Xilio Therapeutics
1.9375 of 5 stars
$9.00
+4.4%
$16.00
+77.8%
-25.7%$57.31M$43.77MN/A76
RNTX
Rein Therapeutics
2.4162 of 5 stars
$0.62
+1.2%
$6.00
+866.3%
-70.8%$56.82MN/AN/A10
ONCY
Oncolytics Biotech
1.6905 of 5 stars
$0.41
-7.2%
$5.00
+1,126.4%
-63.6%$55.70MN/AN/A29

Related Companies and Tools


This page (NASDAQ:ATYR) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners